Overactive Bladder-Pipeline Review, H2 2015

Overactive Bladder-Pipeline Review, H2 2015

  • Products Id :- GMDHC7219IDB
  • |
  • Pages: 127
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Overactive Bladder-Pipeline Review, H2 2015


Global Markets Direct's, 'Overactive Bladder-Pipeline Review, H2 2015', provides an overview of the Overactive Bladder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Overactive Bladder

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Overactive Bladder and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Overactive Bladder pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Overactive Bladder

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Overactive Bladder Overview 10

Therapeutics Development 11

Pipeline Products for Overactive Bladder-Overview 11

Pipeline Products for Overactive Bladder-Comparative Analysis 12

Overactive Bladder-Therapeutics under Development by Companies 13

Overactive Bladder-Therapeutics under Investigation by Universities/Institutes 16

Overactive Bladder-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Overactive Bladder-Products under Development by Companies 20

Overactive Bladder-Products under Investigation by Universities/Institutes 23

Overactive Bladder-Companies Involved in Therapeutics Development 24

Addex Therapeutics Ltd 24

Allergan Plc 25

AltheRx Pharmaceuticals, Inc. 26

Asahi Kasei Pharma Corp. 27

Astellas Pharma Inc. 28

Dong-A Socio Group 29

FemmePharma Global Healthcare, Inc. 30

Ferring International Center S.A. 31

Hydra Biosciences, Inc. 32

Ion Channel Innovations, LLC 33

Ipsen S.A. 34

Jeil Pharmaceutical Co., Ltd. 35

Laboratorios SALVAT S.A. 36

Lipella Pharmaceuticals, Inc. 37

Merck & Co., Inc. 38

Mezzion Pharma Co. Ltd. 39

MI.TO. Technology S.r.L. 40

NeuroSearch A/S 41

Recordati S.p.A. 42

Sanofi 43

Takeda Pharmaceutical Company Limited 44

TARIS BioMedical, Inc. 45

TheraVida, Inc. 46

Toray Industries, Inc. 47

Overactive Bladder-Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Combination Products 49

Assessment by Target 50

Assessment by Mechanism of Action 52

Assessment by Route of Administration 54

Assessment by Molecule Type 56

Drug Profiles 58

(mirabegron + solifenacin succinate)-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

(solifenacin succinate + tamsulosin hydrochloride)-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

abobotulinumtoxin A-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

ADX-71441-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

DA-8010-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

FE-999309-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

HC-067047-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

mirabegron ER-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NS-19504-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

onabotulinumtoxin A-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

oxybutynin chloride-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

oxybutynin hydrochloride-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

pVAX-hSlo-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

REC-0438-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

SAR-244181-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

senrebotase-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules to Antagonize EP1 Receptor for Overactive Bladder-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules to Antagonize TRPV1 for Overactive Bladder-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

solabegron hydrochloride-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

solifenacin succinate-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

solifenacin succinate-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

tacrolimus-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

TAR-302-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

tarafenacin-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

THVD-201-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

THVD-202-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

udenafil-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

vibegron-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Overactive Bladder-Recent Pipeline Updates 100

Overactive Bladder-Dormant Projects 113

Overactive Bladder-Discontinued Products 118

Overactive Bladder-Product Development Milestones 120

Featured News & Press Releases 120

Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder 120

May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 121

May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 122

Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial 123

Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 123

Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder 124

Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 124

May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 125

May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder 125

May 07, 2013: Astellas Pharma Presents Clinical Data On Myrbetriq At American Urological Association Annual Meeting 126

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

Number of Products under Development for Overactive Bladder, H2 2015 11

Number of Products under Development for Overactive Bladder-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 14

Number of Products under Development by Companies, H2 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2015 16

Comparative Analysis by Late Stage Development, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Development, H2 2015 19

Products under Development by Companies, H2 2015 20

Products under Development by Companies, H2 2015 (Contd..1) 21

Products under Development by Companies, H2 2015 (Contd..2) 22

Products under Investigation by Universities/Institutes, H2 2015 23

Overactive Bladder-Pipeline by Addex Therapeutics Ltd, H2 2015 24

Overactive Bladder-Pipeline by Allergan Plc, H2 2015 25

Overactive Bladder-Pipeline by AltheRx Pharmaceuticals, Inc., H2 2015 26

Overactive Bladder-Pipeline by Asahi Kasei Pharma Corp., H2 2015 27

Overactive Bladder-Pipeline by Astellas Pharma Inc., H2 2015 28

Overactive Bladder-Pipeline by Dong-A Socio Group, H2 2015 29

Overactive Bladder-Pipeline by FemmePharma Global Healthcare, Inc., H2 2015 30

Overactive Bladder-Pipeline by Ferring International Center S.A., H2 2015 31

Overactive Bladder-Pipeline by Hydra Biosciences, Inc., H2 2015 32

Overactive Bladder-Pipeline by Ion Channel Innovations, LLC, H2 2015 33

Overactive Bladder-Pipeline by Ipsen S.A., H2 2015 34

Overactive Bladder-Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 35

Overactive Bladder-Pipeline by Laboratorios SALVAT S.A., H2 2015 36

Overactive Bladder-Pipeline by Lipella Pharmaceuticals, Inc., H2 2015 37

Overactive Bladder-Pipeline by Merck & Co., Inc., H2 2015 38

Overactive Bladder-Pipeline by Mezzion Pharma Co. Ltd., H2 2015 39

Overactive Bladder-Pipeline by MI.TO. Technology S.r.L., H2 2015 40

Overactive Bladder-Pipeline by NeuroSearch A/S, H2 2015 41

Overactive Bladder-Pipeline by Recordati S.p.A., H2 2015 42

Overactive Bladder-Pipeline by Sanofi, H2 2015 43

Overactive Bladder-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 44

Overactive Bladder-Pipeline by TARIS BioMedical, Inc., H2 2015 45

Overactive Bladder-Pipeline by TheraVida, Inc., H2 2015 46

Overactive Bladder-Pipeline by Toray Industries, Inc., H2 2015 47

Assessment by Monotherapy Products, H2 2015 48

Assessment by Combination Products, H2 2015 49

Number of Products by Stage and Target, H2 2015 51

Number of Products by Stage and Mechanism of Action, H2 2015 53

Number of Products by Stage and Route of Administration, H2 2015 55

Number of Products by Stage and Molecule Type, H2 2015 57

Overactive Bladder Therapeutics-Recent Pipeline Updates, H2 2015 100

Overactive Bladder-Dormant Projects, H2 2015 113

Overactive Bladder-Dormant Projects (Contd..1), H2 2015 114

Overactive Bladder-Dormant Projects (Contd..2), H2 2015 115

Overactive Bladder-Dormant Projects (Contd..3), H2 2015 116

Overactive Bladder-Dormant Projects (Contd..4), H2 2015 117

Overactive Bladder-Discontinued Products, H2 2015 118

Overactive Bladder-Discontinued Products (Contd..1), H2 2015 119

List of Figures

Number of Products under Development for Overactive Bladder, H2 2015 11

Number of Products under Development for Overactive Bladder-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Products, H2 2015 19

Assessment by Monotherapy Products, H2 2015 48

Assessment by Combination Products, H2 2015 49

Number of Products by Top 10 Targets, H2 2015 50

Number of Products by Stage and Top 10 Targets, H2 2015 50

Number of Products by Top 10 Mechanism of Actions, H2 2015 52

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 52

Number of Products by Routes of Administration, H2 2015 54

Number of Products by Stage and Routes of Administration, H2 2015 54

Number of Products by Molecule Types, H2 2015 56

Number of Products by Stage and Molecule Types, H2 2015 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Addex Therapeutics Ltd

Allergan Plc

AltheRx Pharmaceuticals, Inc.

Asahi Kasei Pharma Corp.

Astellas Pharma Inc.

Dong-A Socio Group

FemmePharma Global Healthcare, Inc.

Ferring International Center S.A.

Hydra Biosciences, Inc.

Ion Channel Innovations, LLC

Ipsen S.A.

Jeil Pharmaceutical Co., Ltd.

Laboratorios SALVAT S.A.

Lipella Pharmaceuticals, Inc.

Merck & Co., Inc.

Mezzion Pharma Co. Ltd.

MI.TO. Technology S.r.L.

NeuroSearch A/S

Recordati S.p.A.


Takeda Pharmaceutical Company Limited

TARIS BioMedical, Inc.

TheraVida, Inc.

Toray Industries, Inc.

Overactive Bladder Therapeutic Products under Development, Key Players in Overactive Bladder Therapeutics, Overactive Bladder Pipeline Overview, Overactive Bladder Pipeline, Overactive Bladder Pipeline Assessment

select a license

Single User License
USD 2000 INR 129780
Site License
USD 4000 INR 259560
Corporate User License
USD 6000 INR 389340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com